1 / 15

Brain Arnab Chakravarti, MD

Brain Arnab Chakravarti, MD. Head & Neck Christine H. Chung, MD. Bioinformatics Joseph O. Deasy, PhD Soren Bentzen, PhD. Lung Quynh Le, MD, PhD. Breast Wendy Woodward, MD, PhD Steven Chimura, MD, PhD. Publications Arnab Chakravarti, MD. Molecular Signatures

brigit
Download Presentation

Brain Arnab Chakravarti, MD

An Image/Link below is provided (as is) to download presentation Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. Content is provided to you AS IS for your information and personal use only. Download presentation by click this link. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server. During download, if you can't get a presentation, the file might be deleted by the publisher.

E N D

Presentation Transcript

  1. Brain Arnab Chakravarti, MD Head & Neck Christine H. Chung, MD Bioinformatics Joseph O. Deasy, PhD Soren Bentzen, PhD Lung Quynh Le, MD, PhD Breast Wendy Woodward, MD, PhD Steven Chimura, MD, PhD Publications Arnab Chakravarti, MD Molecular Signatures Christine H. Chung, MD Sarcoma William Kraybill, MD David Kirsh, MD, PhD Dina Lev, MD, PhD Gastrointestinal Chandan Guha, MD Sunil Krishnan, MD EORTC Eric Deutch, MD Tissue Bank Fred Waldman, MD, PhD Genitourinary Allan Pollack, MD, PhD Protons Jason Efstathiou, DSc, MD Trans-Canada Robert G. Bristow, MD, PhD Matthew B. Parliament, MD Normal Tissue Effects Deborah Citrin, MD Barry Rosenstein, PhD Ulrich Rodeck, MD, PhD Gynecology Joanne Weidhaas, MD, PhD

  2. RTOG Strengths • Unique Mission • Outstanding Scientific Leadership • Transformational Research • Growing Accrual • Translational Research with Funding • Pivotal Phase III Trials • Leader in New Technologies

  3. Strengths • Outstanding Databases • Growing Membership Base • Outstanding Staff in HQ and Biostat • Unique Link with ATC and RPC • Non-Federal Sources of Funding • Unique Relationship with ACR • Core Group of Member Institutions • Canadian-European-Asian Link

  4. Goals of the TRP • Leverage the rapid evolution of translational research to support RTOG’s mission • Representation in TRP • Surgery, Pathology, Medical Oncology, Radiation Oncology, Basic Science, Translational Science, Statistics, Patient Advocacy • New liaisons and subcommittees • ATIC • Breast • Molecular Signatures • Outcomes/Quality of Life, Normal Tissue • Protons • Bioinformatics • Trans-Canada

  5. Operational Roles of TRP • Recruit scientists • Identify promising resources/technologies • Group member education and feedback • Seed grant funding for novel ideas

  6. Process for Evaluating Seed Grant Proposals RTOG HQ External Advisory Committee RTOG Statistics Biospecimen Resource Disease Site Liaisons TRP Chair RTOG Steering Committee Feedback to Applicant RFA and application, www.RTOG.org

  7. Scientific Roles of TRP • Hypothesis generation and validation • Incorporation of TRP endpoints into trials • Trial analysis and factors modeling

  8. Themes of TRP • Identify signatures of resistant local disease • Identify markers for patterns of failure • Identify and improve normal tissue risk prediction models

  9. Required Infrastructure Translational Research • Tumor and Tissue Bank (LDS, Utah) • Biostatistical Link with Clinical Data • Translational Researchers across the globe • Peer-Reviewed Funding (RO1, R29, GO) • RT Delivery Databases (St Louis) • Outcomes Databases (Philadelphia)

  10. Fred Waldman, M.D.,Ph.D.Jeff Simko, M.D., Ph.D. Richard Jordan, Ph.D., DDS Ken Aldape, M.D., Ph.D. Sandy DeVries, M.S. RTOG Biospecimen Resource

  11. Inventory as of January, 2010 • Brain 3159 cases/ 35 trials • GU 10586 cases / 32 trials • GI 3032 cases / 18 trials • Gyn 283 cases / 7 trials • Head/Neck 4220 cases / 17 trials • Lung 448 cases / 13 trials • Sarcoma 213 cases / 8 trials • TMAs 27 TMAs Total 21,977 cases / 132 trials (2264 cases w buffy coat, 2156 plasma, 2438 serum)

  12. Outcomes = physics and biology Outcome variation Dosimetric factors Biomarkers/biological factors Statistical models of combined factors Joe Deasy, Wash Univ.

  13. Global RTOG Strategy Candidate gene polymorphisms and RT/Chemo toxicity Opportunities for survivorship studies

  14. Hypothesis • Patients with identical DVHs/field size will have different toxicities that are governed by gene polymorphisms that influence signal amplification from DNA damaging agents.

  15. Research Links • Links to National Research Community • NCI Steering Committee Involvement • SPORE/PO1 Collaborations • SWOG Interactions • AACR • ASTRO (RTOG Foundation) • RFA on RTOG website • Links to International Research Community • EORTC and NCIC Representation

More Related